Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.79 |
| ▸ | GAK | O14976 | 1/20 | 0.79 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.69 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.69 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.65 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.65 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.65 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.65 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.65 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.65 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16212314 | 0.93 | EGFR (0.70) | EGFRGAKERBB2ERBB4 | |
| SCHEMBL2533904 | 0.92 | EGFR (0.70) | EGFRGAKERBB2ERBB4 | |
| SCHEMBL16212746 | 0.91 | EGFR (0.69) | EGFRGAKERBB2ERBB4 | |
| SCHEMBL29719074 | 0.91 | EGFR (0.69) | EGFRGAKERBB2ERBB4 | |
| SCHEMBL15928200 | 0.90 | EGFR (0.67) | EGFRGAKERBB2ERBB4HDAC3 | |
| SCHEMBL15928186 | 0.90 | EGFR (0.67) | EGFRGAKERBB2ERBB4HDAC3 | |
| SCHEMBL22983584 | 0.89 | EGFR (0.67) | EGFRGAKERBB2ERBB4 | |
| SCHEMBL29719131 | 0.89 | EGFR (0.67) | EGFRGAKERBB2ERBB4 | |
| SCHEMBL17538555 | 0.89 | EGFR (0.66) | EGFRGAKERBB2ERBB4HDAC3 | |
| SCHEMBL2509312 | 0.89 | EGFR (1.00) | EGFRGAKERBB2ERBB4HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10795469-B2 | Laminate containing conductive fiber, photosensitive conductive film, method for producing conductive pattern, conductive pattern substrate, and touch panel | HITACHI CHEMICAL COMPANY, LTD. (JP) | 2020-10-06 | — | — | US | disclosed |
| CN-107556295-B | Quinazoline derivatives and process for their preparation | 正大天晴药业集团股份有限公司 | 2020-09-04 | — | — | CN | disclosed |
| EP-3050880-B1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CANCER | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2019-06-19 | — | — | EP | disclosed |
| US-9725439-B2 | Quinazoline derivative and preparation method therefor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-08-08 | — | — | US | disclosed |
| US-9556191-B2 | Aminoquinazoline derivatives and their salts and methods of use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-01-31 | — | — | US | disclosed |
| EP-3050880-A1 | QUINAZOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR | Chia Tai Tianqing Pharmaceutical Group Co.,Ltd (CN) | 2016-08-03 | — | — | EP | disclosed |
| US-20160216790-A1 | LAMINATE CONTAINIG CONDUCTIVE FIBER, PHOTOSENSITIVE CONDUCTIVE FILM, METHOD FOR PRODUCING CONDUCTIVE PATTERN, CONDUCTIVE PATTERN SUBSTRATE, AND TOUCH PANEL | RESONAC CORPORATION (JP) | 2016-07-28 | — | — | US | disclosed |
| US-20160214964-A1 | QUINAZOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2016-07-28 | — | — | US | disclosed |
| US-20160039838-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-02-11 | — | — | US | disclosed |
| WO-2014177038-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-11-06 | — | — | WO | disclosed |
| US-8309563-B2 | Quinazoline derivatives useful as anti-tumor medicament | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2012-11-13 | — | — | US | disclosed |
| US-8044063-B2 | Quinazoline derivatives useful as anti-tumor medicament | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2011-10-25 | — | — | US | disclosed |
| US-20110245246-A1 | Quinazoline Derivatives Useful as Anti-Tumor Medicament | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2011-10-06 | — | — | US | disclosed |
| EP-2248806-A2 | Quinazoline derivatives as tyrosine kinase inhibitors | Shanghai Allist Pharmaceuticals, Inc. (CN) | 2010-11-10 | — | — | EP | disclosed |
| US-20080300248-A1 | Quinazoline Derivatives, Preparation Methods and Uses Thereof | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2008-12-04 | — | — | US | disclosed |
| EP-1990337-A1 | QUINAZOLINE DERIVATIVES,PREPARATION METHODS AND USES THEREOF | SHANGHAI ALLIST PHARMACEUTICAL., INC. (CN) | 2008-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039838-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE THEREOF | WNK1, ABL1, NEK4 | EGFR 1223/4885GAK 205/4885ERBB2 368/4885 |
| US-20160214964-A1 | QUINAZOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR | WEE1, WEE2, EGFR | EGFR 3/4885GAK 580/4885ERBB2 4/4885 |
| US-20110245246-A1 | Quinazoline Derivatives Useful as Anti-Tumor Medicament | TP53, NQO2, TOP1 | EGFR 3303/4885GAK 1610/4885ERBB2 3151/4885 |
| US-20080300248-A1 | Quinazoline Derivatives, Preparation Methods and Uses Thereof | NQO2, AQP3, AQP1 | EGFR 2954/4885GAK 1241/4885ERBB2 2993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.